Why integrated drug–device testing is critical in autoinjector development

Published: 8-Jul-2025 Featured companies: Solvias AG
Manufacturing Regulatory Drug Delivery

A guide to robust testing strategies for accelerating timelines and reducing regulatory risk

With rising biologic complexity and stricter regulations, robust testing in autoinjector development is essential. Download the white paper for a comprehensive guide to functional, E&L, CCIT and stability testing in NIS-AUTO – designed to accelerate timelines and mitigate regulatory risks.

Access the white paper

Featured companies

Solvias helps innovative companies advance their path to commercialization with CMC analytical solutions powered by deep scientific expertise and a relentless focus on our...
  • Companies:
  • Solvias AG
See more

You may also like

Manufacturing

Solvias expands US biologics capabilities with cGMP-ready RTP facility

Read more
Milestone supports advanced therapies from early development to commercial release

Trending Articles

  1. Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
  2. When the chemistry is right: Vetter expands capacities with a pure water generator from Pharmatec The production of injectable active pharmaceutical ingredients (APIs) is a highly complex process that leaves no room for error
  3. Meet Navetta: new approach to safety testing of drugs and particles Turn inhalation research upside down
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Pharma outsourcing trends 2025: partnership, precision and resilience The Bachem team shares its insights on the evolving relationship between pharma companies and CDMOs
  5. Sustainability that performs: how GEA is building a better future for pharma By embedding ESG principles into pharmaceutical manufacturing, GEA is delivering measurable sustainability performance without compromising compliance or productivity

Relevant companies

See more

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Solvias expands US biologics capabilities with cGMP-ready RTP facility

Milestone supports advanced therapies from early development to commercial release
Manufacturing

CMC Issues are a Leading Cause of Cell & Gene Therapies Clinical Holds

Overcoming CMC challenges to accelerate cell and gene therapy approvals
Manufacturing

Did you know? USP compliance is expected by 2026

Ensuring compliance and safety in single-use manufacturing
Manufacturing

Solvias to build Biologics and Cell & Gene Therapy testing centre in Research Triangle Park

Global provider continues to expand analytical service capabilities for life science companies developing advanced treatments for cancer and rare diseases
Manufacturing

Solvias to perform release testing on world’s first CRISPR-based gene-editing therapy

Global provider signs long-term agreement with Vertex Pharmaceuticals for CASGEVY (trademarked)
Manufacturing

Solvias acquires Cergentis to boost biologics testing capabilities

The pharma testing company has made the acquisition to supports the increasing number of global pharmaceutical, biotech, and contract development and manufacturing organisations developing genetically engineered therapies
Manufacturing

Hovione and Solvias announce a collaboration to improve drug solubility

Combines the strengths of each company
Subscribe now